Ascendis Pharma A/S

NasdaqGS:ASND

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

Denmark

Market Cap

USD 10.46 B

Share Price

USD 172.95

Avg Daily Volume

505,371

Change (1 day)

-0.03%

Change (1 year)

30.38%

Change (YTD)

25.63%

Ascendis Pharma A/S Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending March 31, 2025: -166.27%

Ascendis Pharma A/S Return on Capital Employed (ROCE) is -166.27% for the Trailing 12 Months (TTM) ending March 31, 2025, a 114.84% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Ascendis Pharma A/S Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending March 31, 2024 was -77.39%, a 75.18% change year over year.
Ascendis Pharma A/S Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -44.18%, a 6.71% change year over year.
Ascendis Pharma A/S Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending March 31, 2022 was -41.40%, a -16.08% change year over year.
Ascendis Pharma A/S Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending March 31, 2021 was -49.33%, a 56.78% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Return on Capital Employed (ROCE)	Return on Equity (ROE)	Return on Assets (ROA)	Revenue Per Share

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	1,017
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.